ANDREW VOLIN: Open Payments
NPI 1093979882 · LAS VEGAS, NV. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$6,473 in 130 payments from 15 companies in 2025. Trend: 2023 $3,195 · 2024 $4,723 · 2025 $6,473
Food & beverage: $3,773Consulting: $2,700
| Company | Payments | Amount |
|---|---|---|
| EMD Serono, Inc. | 37 | $4,144 |
| ABBVIE INC. | 28 | $690 |
| Biogen, Inc. | 12 | $549 |
| TG Therapeutics, Inc. | 14 | $327 |
| Novartis Pharmaceuticals Corporation | 17 | $245 |
| PFIZER INC. | 9 | $176 |
| E.R. Squibb & Sons, L.L.C. | 1 | $117 |
| GENZYME CORPORATION | 2 | $45 |
| Lundbeck LLC | 3 | $44 |
| Amgen Inc. | 1 | $34 |
Products named: Mavenclad, TYSABRI, BRIUMVI, QULIPTA, UBRELVY, KESIMPTA, NURTEC ODT, ZEPOSIA.
Industry payments across NV — which companies pay providers there.
